Research comparison
BPC-157 vs TB-500
BPC-157 and TB-500 are the two synthetic peptides most often discussed together in tissue-repair research, and they are frequently confused. They are unrelated molecules with different origins, different proposed mechanisms and different bodies of evidence.
This page sets the two research profiles side by side. Every statement below is drawn from the full profiles, which carry the citations; nothing here is a claim about effects in people.
| BPC-157 | TB-500 | |
|---|---|---|
| Category | Peptide | Peptide |
| Highest evidence | Animal — evidence level 2 of 4: Animal evidence Findings come from studies in living non-human animals. Species differences in physiology, metabolism and dosing mean animal results frequently do not carry over to humans. | In vitro — evidence level 1 of 4: In-vitro evidence Findings come from cells, tissues or biochemical systems studied outside a living organism. Such findings describe what a compound can do in a controlled system, not what it does in a person. |
| UK regulatory status | Experimental — UK regulatory status: Experimental — not authorised for human use in the UK A compound appearing in research literature that holds no UK authorisation for human use in any indication. | Experimental — UK regulatory status: Experimental — not authorised for human use in the UK A compound appearing in research literature that holds no UK authorisation for human use in any indication. |
| Research areas | Gastrointestinal models; Tendon and ligament models; Angiogenesis | Cytoskeletal biology; Tissue repair models |
| Verified citations | 5 | 4 |
BPC-157
A synthetic 15-amino-acid peptide derived from a sequence reported in gastric juice, studied predominantly in animal injury models.
BPC-157 is a synthetic pentadecapeptide whose sequence corresponds to a partial fragment of a larger protein reported in human gastric juice. It is proposed to act on the nitric oxide system, on VEGFR2-linked angiogenic signalling, and on the focal adhesion kinase and paxillin pathway associated with cell adhesion and migration. These mechanisms are inferred from cell-culture and rodent work and should be read as proposed rather than established in humans.
TB-500
A synthetic seven-residue fragment of thymosin beta-4, containing the actin-binding motif. It is a different molecule from the full-length protein.
TB-500 is a synthetic short peptide corresponding to the N-terminally acetylated 17–23 fragment of human thymosin beta-4, the region containing the actin-binding motif. Thymosin beta-4 itself is a 43-amino-acid protein that binds monomeric actin and sequesters it from polymerisation, and is proposed to influence cell migration, angiogenesis and inflammatory signalling. TB-500 is proposed to reproduce the actin-binding portion of that activity, but it is a chemically distinct molecule from the parent protein and its own pharmacology is far less characterised.
How the research differs
Different molecular origins
BPC-157 is a fifteen-amino-acid synthetic peptide whose sequence corresponds to a partial fragment of a protein reported in human gastric juice. TB-500 is a seven-residue synthetic fragment of thymosin beta-4 — specifically the region containing the actin-binding motif — and is a different molecule from the full-length 43-amino-acid protein, a distinction the literature itself is often loose about.
Different proposed mechanisms
The mechanisms under investigation barely overlap. For BPC-157, published work proposes activity on the nitric oxide system, VEGFR2-linked angiogenic signalling, and the focal adhesion kinase pathway. For TB-500, the investigated mechanism runs through actin: the parent protein binds monomeric actin and sequesters it from polymerisation, and the fragment carries the motif responsible for that binding. One line of research is about signalling; the other is about the cytoskeleton.
Different evidence maturity
Neither compound has controlled human data. The BPC-157 literature is predominantly animal-model work — gastrointestinal, tendon and ligament injury models in particular. The TB-500 fragment itself is thinner still: most published work concerns full-length thymosin beta-4, and evidence specific to the fragment is largely in-vitro. The full profiles grade this precisely, and their study-limitations sections apply in full.
The same regulatory position
Here the two do not differ: neither BPC-157 nor TB-500 is an authorised medicine anywhere. Both are experimental substances, and both profiles record the UK position with a cited source.